@ARTICLE{10.3389/ti.2021.10184, AUTHOR={Miyahara, Naofumi and Benazzo, Alberto and Oberndorfer, Felicitas and Iwasaki, Akinori and Laszlo, Viktoria and Döme, Balasz and Hoda, Mir Ali and Jaksch, Peter and Klepetko, Walter and Hoetzenecker, Konrad}, TITLE={MiR-21 in Lung Transplant Recipients With Chronic Lung Allograft Dysfunction}, JOURNAL={Transplant International}, VOLUME={35}, YEAR={2022}, URL={https://www.frontierspartnerships.org/articles/10.3389/ti.2021.10184}, DOI={10.3389/ti.2021.10184}, ISSN={1432-2277}, ABSTRACT={Background: Micro-RNA-21 (miR-21) is a post-translational regulator involved in epithelial-to-mesenchymal transition (EMT). Since EMT is thought to contribute to chronic lung allograft dysfunction (CLAD), we aimed to characterize miR-21 expression and distinct EMT markers in CLAD.Methods: Expression of miR-21, vimentin, Notch intracellular domain (NICD) and SMAD 2/3 was investigated in explanted CLAD lungs of patients who underwent retransplantation. Circulating miR-21 was determined in collected serum samples of CLAD and matched stable recipients.Results: The frequency of miR-21 expression was higher in restrictive allograft syndrome (RAS) than in bronchiolitis obliterans syndrome (BOS) specimens (86 vs 30%, p = 0.01); Vimentin, NICD and p-SMAD 2/3 were positive in 17 (100%), 12 (71%), and 7 (42%) BOS patients and in 7 (100%), 4 (57%) and 4 (57%) RAS cases, respectively. All four markers were negative in control tissue from donor lungs. RAS patients showed a significant increase in serum concentration of miR-21 over time as compared to stable recipients (p = 0.040).Conclusion: To the best of our knowledge this is the first study highlighting the role miR-21 in CLAD. Further studies are necessary to investigate the involvement of miR-21 in the pathogenesis of CLAD and its potential as a therapeutic target.} }